What question did this study set out to answer?

This update aims to summarize significant changes in the NCCN guidelines for prostate cancer care for 2026.

May 17, 2026Journal of the National Comprehensive Cancer Network4 citationsOpen Access

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026

DSDaniel E. SprattCleveland Clinic SSSandy SrinivasUniversity of California, Irvine NANabil AdraIndiana University Health

Key Points

This update aims to summarize significant changes in the NCCN guidelines for prostate cancer care for 2026.
Updated recommendations for staging and risk assessment in prostate cancer management.
Discussed panel insights on nonmetastatic disease and treatment approaches.
Evaluated the role of active surveillance and focal therapy for newly diagnosed patients.
Elimination of the very-low-risk prostate cancer group from guidelines.
Revised principles for active surveillance were proposed to enhance patient management.
Increased caution advised regarding the use of focal therapy in newly diagnosed cases.

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.

AI에게 질문

Bookmark

View Full Paper